Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics

Conditions

• Cancer
• mCRC

Interventions

• DRUG: HLX05
• DRUG: EU-Erbitux®
• DRUG: US-Erbitux®
• DRUG: CN-Erbitux®

Sponsor

Shanghai Henlius Biotech